Skip to main content

Table 1 Patient characteristics

From: 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

  FDG study (N = 22) FLT study (N = 27)
Mean (range) Mean (range)
Age at registration, years 62.0 (51–80) 58.7 (28–74)
Days between scans 19.5 (7–40) 27.2 (6–64)
Days between 1st scan and surgery (AI therapy duration) 22.5 (9–42) 31.6 (9–69)
Days between 2nd scan and surgery 3.0 (1–6) 4.3 (1–12)*
  N (%) N (%)
Female sex 22 (100%) 27 (100%)
Race
 Caucasian/White 19 (86%) 22 (82%)
 Black/African American 2 (7%)
 Asian 1 (5%) 3 (11%)
 Pacific Islander 2 (9%)
Ethnicity
 Not hispanic or latino 21 (95%) 26 (96%)
 Hispanic or latino 1 (5%) 1 (4%)
Menopausal status
 Postmenopausal 22 (100%) 20 (74%)
 Premenopausal 7 (26%)
Aromatase inhibitor
 Anastrozole 18 (82%) 22 (81%)
 Letrozole 4 (18%) 5 (19%)
  1. *1 patient had 12 days between FLT scan and surgery, the remaining were 7 days or less